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CC BY-NC-ND license (http://creativeBackground/Purpose: The follicular variant of papillary thyroid carcinoma (FVPTC) is the most
common variant of papillary thyroid carcinoma (PTC). A previous population-based study re-
vealed its clinical behavior as a mix of classic papillary thyroid carcinoma (C-PTC) and follicular
thyroid carcinoma. Whereas locoregional extension was lower in FVPTC than in C-PTC, the
distant metastasis rate was higher in FVPTC than in C-PTC. The aim of this study was to eval-
uate the risk factors of distant metastasis in FVPTC postoperatively.
Methods: A retrospective review of 359 patients with final pathological diagnosis of FVPTC
treated at Chang Gung Memorial Hospital between January 2000 and January 2014 was per-
formed. After excluding patients who had inadequate pathological data for analysis or did
not attend regular follow up for >1 year, 346 patients were included in this study. Univariate
and multivariate statistical analyses were performed to determine the significance of various
factors.
Results: Of the 346 patients with FVPTC, 19 (5.5%) had lymph node metastases and 32 (9.2%)
had distant metastases. Two positive and one negative risk factors were predictive for distant
metastasis using multivariate analysis: angiolymphatic invasion [odds ratio (OR), 3.085; 95%
confidence interval (CI), 1.008e9.442], extrathyroidal extension (OR, 3.929; 95% CI, 1.330
e11.602), and encapsulation (OR, 0.361; 95% CI, 0.154e0.850).ave no conflicts of interest relevant to this article.
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666 Y.-R. Li et al.Conclusion: The presence of angiolymphatic invasion, extrathyroidal extension, or nonencap-
sulation was associated with distant metastasis in FVPTC in this study. In FVPTC patients, post-
operative investigation for distant metastasis may be warranted by the presence of these two
positive risk factors or the absence of the one negative risk factor.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
The follicular variant of papillary thyroid carcinoma
(FVPTC) is the most common variant of papillary thyroid
cancer (PTC) and accounts for approximately 10e15% of all
PTC cases.1e3 The FVPTC was first defined in 1950 by
Dailey et al,4 who observed that FVPTC was a neoplasm
characterized by follicular architecture and the nuclear
features of conventional PTC. According to past reports, in
general, the long-term outcome of classic papillary thyroid
carcinoma (C-PTC) and FVPTC are similar, and patients in
both groups should be treated in the same way.5 However,
the clinical behavior of FVPTC may be different from that
of C-PTC. A previous population-based study revealed its
clinical behavior as a mix of C-PTC and follicular thyroid
carcinoma (FTC).6 Although locoregional extension was
lower in FVPTC than in C-PTC, the distant metastasis rate
was higher in FVPTC than in C-PTC.6 Unlike the indolent
clinical course that most FVPTC patients experience, pa-
tients with distant metastasis, either at initial diagnosis
or at recurrence, have a relatively poor outcome. The
aim of this study was to retrospectively analyze the
possible predictors of distant metastasis in FVPTC after
thyroidectomy.Patients and methods
A retrospective review of a total of 359 patients with final
pathological diagnosis of FVPTC who were treated at Chang
Gung Memorial Hospital (CGMH) between January 2000 and
January 2014 was performed. After excluding patients who
had inadequate pathological data for analysis or who did
not attend regular follow up for >1 year, a total of 346
patients were finally included in this study. All patients
were staged using the International Union Against Cancer
TumoreNodeeMetastasis (TNM) criteria (6th edition).7
Permission was obtained from the Institutional Review
Board (IRB) and ethics committees of CGMH for a retro-
spective review of the medical records of the study par-
ticipants. The IRB waived the requirement for obtaining
informed consent. Confidentiality of the research partici-
pants was maintained in accordance with the requirements
of the IRB of CGMH.
Ultrasonographic features, including solid/cystic/mixed
lesion, marked hypoechogenicity, taller-than-wide shape,
infiltrative margin, and micro- or macrocalcification were
recorded and classified into PTC-like or follicular neoplasm
(FN)-like nodules according to their ultrasonographic fea-
tures as described in a recent study.8 PTC-like nodules weredefined as having at least one of the following malignant
features:marked hypoechogenicity, taller-than-wide shape,
infiltrative margin, and micro- or macrocalcifications.
Conversely, FN-like nodules revealed a lesion without ma-
lignant features.
Fine-needle-aspiration cytology (FNAC) was performed
in suspicious nodules after thyroid ultrasonography. The
aspirate was expressed on frosted-end glass slides, air-
dried, and stained, using the Romanowsky-based method
as described by Lin et al.9 Because a diagnosis of FVPTC
is made according to finding the typical nuclear features
in classic PTC, we reported preoperation cytology in
three main categories for triage of treatment: benign,
FN, and malignant for PTC. Intraoperative frozen section
(FS) analysis was performed on the cut surface of the
thyroid nodules, including the interface between the
nodule and adjacent thyroid tissue. Two to three FSs
were regularly analyzed according to the size of the
nodules. In the majority of cases, 30 minutes was needed
to complete the analysis of the FS. Specimens for per-
manent pathology were fixed in 10% buffered formalin
followed by paraffin embedding. Serial sections were
stained with hematoxylineeosin, and the slides were
analyzed by experienced pathologists at our medical
center.
Postoperative serum thyroglobulin (Tg) levels were
detected using an immunoradiometric assay kit (CIS Bio
International, Codolet, France). In most high-risk patients
who had incomplete tumor resection or complete tumor
resection using a scoring system based on metastasis, age,
completeness of resection, invasion, and size (MACIS
scores) 6, thyroid remnant ablation with radioactive io-
dide (131I) was performed 4e6 weeks after surgery. The 131I
ablation dose for most patients was 1.1e3.7 GBq
(30e100 mCi). A whole-body scan (WBS) was obtained 1
week after 131I administration using a dual-head gamma
camera (GE Infinia Hawkeye 4, Haifa, Israel) equipped with
a high-energy collimator. Cases where the foci of 131I up-
take extended beyond the thyroid bed were classified as
distant metastases, and further confirmatory study was
performed. Patients diagnosed with distant metastasis
would be administered with higher therapeutic doses of 131I
[3.7e7.4 GBq (100e200 mCi)] with the following thera-
peutic WBS. Physiological uptakes including thymus, breast,
salivary glands, liver, and gastrointestinal tract were
excluded by experienced nuclear medicine specialists with
the information obtained from clinical history, physical
examination, serum Tg level, and appropriate second im-
aging investigations if indicated. A repeat therapeutic dose
of 3.7e7.4 GBq was used at an interval of 6e12 months.
Risk factors of distant metastasis in FVPTC 667Distant metastases were identified using the patholog-
ical report from the surgical specimen or by the presence of
131I uptake on diagnostic/therapeutic scans obtained 1e2
months after final thyroidectomy in patients with elevated
Tg and confirmed with/without a second imaging modality
(plain chest radiography, computed tomography, bone
scintigraphy, positron emission tomography, and magnetic
resonance imaging).
The following data were extracted from the admission
records for analysis: age, sex, primary tumor size, ultra-
sonographic features, FNAC results, operative methods,
pathological findings, TNM staging, 1 month postoperative
serum Tg levels, anti-Tg antibody, the cumulative dose of
therapeutic 131I, and survival status.
Statistical analysis
Continuous data with normal distribution are expressed as
mean  standard deviation; otherwise, data are expressed
as the median with the range. Categorical data are
expressed as numbers with percentage. Fisher’s exact and
chi-square tests were used to analyze categorical variables.
The two-sample Student t test and ManneWhitney U test
were used to analyze normal and non-normal distribution of
continuous variables, respectively. Univariate statistical
analyses were performed to determine the significance of
various factors. Significant factors after univariate analysisTable 1 Clinicopathological characteristics of 346 patients with
FVPTC w
Age (y) 44.64 
Male 70 (22.3
Pre-OP echo (solid/cystic/mixed mass) 233/7/3
Marked hypoechogenicity 78 (24.8
Taller-than-wide shape 26 (8.3)
Infiltrative margin 106 (33.
Micro- or macrocalcification 62 (19.7
Tumor size (cm)a 2.7 (1.7
Multifocality 106 (33.
Stromal invasion 24 (7.6)
Angiolymphatic invasion 16 (5.1)
Encapsulation 161 (51.
Capsule invasion 30 (9.6)
Extrathyroidal extension 12 (3.8)
Pre-OP cytology (benign/FN/malignant for PTC) 90/120/
Frozen section (undeterminate/malignant) 136/104
Operative method (partial/total thyroidectomy/total
thyroidectomy with LND)
49/239/
TNM stage (stage1/2/3/4) 211/58/
Post-OP 1 mo Tg (ng/mL) a 3.53 (0e
Post-OP 131I accumulative dose (mCi) a 60 (30e
Median follow-up year a 4.91 (2.
Survival (yes/no) 310/4
Disease-specific mortality 0
Values in parentheses are percentages unless indicated otherwise.
DM Z distant metastasis; FN Z follicular neoplasm; FVPTC
OP Z intraoperative; LND Z lymph node dissection; Pre-OP Z preop
cinoma; Tg Z thyroglobulin; TNM Z tumorenodeemetastasis.
a Values are median (range); , standard deviation.were analyzed using a forward stepwise logistic regression.
Overall survival and carcinoma-specific survival were esti-
mated using the KaplaneMeier method and log-rank test.
Statistical significance was set at a p value  0.05. All an-
alyses were performed using IBM SPSS Statistics for Win-
dows, Version 22.0. (IBM Corp., Armonk, NY, USA).
Results
Of the 346 patients with FVPTC, 19 (5.5%) had lymph node
metastasis and 32 (9.2%) had distant metastasis. Among the
distant metastasis group, 25 (78.1%) patients were diag-
nosed prior to or 1e2 months after thyroidectomy and
seven (21.9%) patients were diagnosed with distant
metastasis during the follow-up period. The average dura-
tion between diagnosis and recurrence with distant
metastasis was 1.41 years.
The most common site of distant metastasis was the
lungs (15 cases, 46.87%), followed by the bones (14 cases,
43.75%), both the lungs and bones (2 cases, 6.25%), and the
brain (1 case, 3.13%). There were eight patients diagnosed
with distant metastases prior to thyroidectomy by tissue
proof after biopsy for suspected bone or lung cancer.
Among them, seven patients had bone pain owing to sus-
pected bone tumors, and one patient had incidental pul-
monary nodules observed on chest radiography. Of the
remaining patients with distant metastases, six patientsFVPTC.
ithout DM (n Z 314) FVPTC with DM (n Z 32) p
13.67 49.6  13.7 0.054
) 11 (34.4) 0.124
8 21/1/6 0.494
) 13 (40.6) 0.071
4 (12.5) 0.510
8) 18 (56.3) 0.015
) 11 (34.4) 0.070
e4.0) 2.75 (1.22e5.0) 0.395
8) 14 (43.8) 0.258
4 (12.5) 0.311
5 (15.6) 0.034
3) 8 (25) 0.005
6 (18.8) 0.124
6 (18.8) 0.003
46 10/12/2 0.332
6/16 0.008
26 1/26/5 0.170
40/4 4/10/1/18 <0.001
11.43) 129.5 (15.93e4271.25) <0.001
100) 290 (100e675) <0.001
83e7.41) 4.50 (2.81e7.41) 0.996
23/9 <0.001
7 <0.001
Z follicular variant of papillary thyroid carcinoma; Intra-
erative; Post-OP Z postoperative; PTC Z papillary thyroid car-
Table 2 Analysis of clinicopathological characteristics of PTC-like FVPTCs compared with FN-like FVPTCs according to ul-
trasonographic findings.
PTC-like nodules (n Z 184) FN-like nodules (n Z 106) p
Age (y) 46.96  13.07 41.91  14.30 0.002
Male 40 (21.7) 26 (24.5) 0.585
Tumor size (cm) a 2.50 (1.55e3.72) 3.2 (2.2e4.2) 0.002
Multifocality 73 (39.7) 25 (23.6) 0.005
Stromal invasion 21 (11.4) 3 (2.8) 0.011
Angiolymphatic invasion 14 (7.6) 5 (4.7) 0.338
Encapsulation 75 (40.8) 67 (63.2) <0.001
Capsule invasion 18 (9.8) 13 (12.3) 0.510
Extrathyroidal extension 13 (7.1) 2 (1.9) 0.055
Lymph node metastasis 17 (9.2) 1 (0.9) 0.005
Distant metastasis 25 (13.6) 3 (2.8) 0.003
Values in parentheses are percentages unless indicated otherwise.
FN Z follicular neoplasm; FVPTC Z follicular variant of papillary thyroid carcinoma; PTC Z papillary thyroid carcinoma.
a Values are median (range); , standard deviation.
Table 3 Risk factors of distant metastasis in univariate
analysis.
Odds ratio p
Age (y) 1.027 (0.999e1.055) 0.055
Male 1.826 (0.840e3.969) 0.129
Tumor size 1.152 (0.945e1.404) 0.161
Multifocality 1.526 (0.731e3.188) 0.261
Stromal invasion 1.726 (0.559e5.329) 0.343
Angiolymphatic
invasion
3.449 (1.173e10.143) 0.024
Encapsulation 0.317 (0.138e0.727) 0.007
Capsule invasion 2.185 (0.833e5.729) 0.112
Extrathyroidal
extension
5.808 (2.051e16.741) 0.001
Lymph node
metastasis
3.968 (1.328e11.855) 0.014
PTC-like echo
features
5.398 (1.589e18.339) 0.007
Marked
hypoechogenicity
2.044 (0.929e4.498) 0.075
Taller-than-wide
shape
1.513 (0.487e4.699) 0.474
Infiltrative margin 2.649 (1.177e5.963) 0.019
Micro- or
macrocalcification
2.087 (0.928e4.693) 0.075
Values in parentheses are 95% confidence intervals.
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pathological tissue observations and results for 18 patients
were confirmed by uptake of diagnostic or therapeutic 131I
WBS combined with elevated Tg (median 193 ng/mL, range
22.6e4398.5) and confirmed with/without a second imaging
modality (1 with plain chest radiography, 10 with chest
computed tomography, 3 with bone scintigraphy, 1 with
positron emission tomography and 1 with magnetic reso-
nance imaging).
The mean age was 44.64  13.67 years for the 314 FVPTC
patients without distant metastasis and 49.6  13.7 years
for the 32 FVPTC with distant metastasis. The FVPTC
without distant metastasis group comprised 70 (22.3%)
men, and the FVPTC with distant metastasis group
comprised 11 (34.4%) men. There were no significant dif-
ferences in age and sex between these two groups. Table 1
summarizes the clinicopathological characteristics of pa-
tients in FVPTC with and without distant metastasis.
Ultrasonographic findings of the nodules were predomi-
nantly solid (83%), however, only 26.3% of the nodules
showed marked hypoechogenicity (Table 1). After chi-
square test was applied for these echo features, only the
infiltrative margin was more frequent in FVPTC with distant
metastasis than those without distant metastasis (56.3% vs.
33.8%; p Z 0.015). The results from ultrasonography
revealed that the rates of both lymph node and distant
metastasis were significantly higher in PTC-like nodules
than in FN-like nodules (Table 2).
The sensitivity of diagnosis for FVPTC using FNAC and
intraoperative FS was 17.14% and 45.80%, respectively. One
hundred and thirty-two cases of FVPTC (47.14%) were
diagnosed as FN by using FNAC in this study. Of these 132
patients diagnosed as FN by FNAC, only 48 (36.36%) patients
can be recognized as FVPTC with intraoperative FS analysis;
the remaining patients were diagnosed on the basis of the
permanent pathologic sections. As a result, 53 (40.15%)
patients received a second operation to complete
thyroidectomy.
In pathological findings, the primary tumor size, and the
percentage of lesions with multifocality, stromal invasion,
angiolymphatic invasion, nonencapsulation, capsuleinvasion, extrathyroidal extension, and lymph node
metastasis were higher in the FVPTC with distant metas-
tasis group than in the group without distant metastasis.
Angiolymphatic invasion, nonencapsulation, extrathyroidal
extension, and lymph node metastasis were significantly
higher in the distant metastasis group.
Based on the univariate analysis (Table 3), six factors
were associated with distant metastasis: infiltrative
margin, PTC-like nodules, angiolymphatic invasion, extra-
thyroidal extension, lymph node metastasis, and encapsu-
lation. After a forward stepwise logistic regression (Table
Table 4 Risk factors of distant metastasis in a forward
stepwise logistic regression.
Odds ratio p
Angiolymphatic invasion 3.085 (1.008e9.442) 0.048
Extrathyroidal extension 3.929 (1.330e11.602) 0.013
Encapsulation 0.361 (0.154e0.850) 0.020
Values in parentheses are 95% confidence intervals.
Risk factors of distant metastasis in FVPTC 6694), angiolymphatic invasion, extrathyroidal extension, and
encapsulation were each independently predictive for
distant metastasis. One month postoperative serum Tg
levels in the distant metastasis group were significantly
higher than those in the group without distant metastasis
(Table 1; p < 0.001). However, in our study, 1 month
postoperative serum Tg levels were classified as a diag-
nostic tool with the imaging study. Therefore, the 1 month
postoperative serum Tg level was excluded from the
multivariate analysis for predictors of distant metastasis.
Figure 1 shows the KaplaneMeier-based estimation of
the overall and disease-specific survival rates of FVPTC
patients with or without distant metastasis. The 1-year, 5-
year, and 10-year overall survival rates of patients with or
without distant metastasis were 100% versus 99.6%, 71%
versus 99.2%, and 54.2% versus 98.5%, respectively
(p < 0.001; Figure 1A). In addition, the 1-year, 5-year, and
10-year disease-specific survival rates of patients with or
without distant metastasis were 100% versus 100%, 77.2%
versus 100%, and 58.9% versus 100%, respectively
(p < 0.001; Figure 1B), illustrating relatively poorer
disease-specific survival in the distant metastasis group.
Discussion
A recent study reported that the distinct biologic behavior
of FVPTC can be predicted based on its ultrasonographic
features, and that PTC-like FVPTC had a higher rate ofFigure 1 KaplaneMeier (A) overall and (B) disease-specific surviv
carcinoma (FVPTC) with and without distant metastasis.extrathyroidal extension, more frequent lymph node
metastasis, and a more advanced stage than FN-like
FVPTC.8 In our study, PTC-like nodules had significantly
higher rates of both lymph node metastasis and distant
metastasis (p Z 0.005 and p Z 0.003, respectively). How-
ever, possibly owing to missing ultrasonographic features
data in 56 patients, the rate of extrathyroidal extension
was higher in PTC-like FVPTC than in FN-like FVPTC,
although it was not statistically significant (p Z 0.055).
In most of the cases, FVPTC could not be clearly defined
on FNAC. The main reasons for this were the absence of the
typical nuclear features of C-PTC and the overlapping
features with benign and other neoplastic follicular
lesions.10e14 According to previous studies, the sensitivity
of FNAC for FVPTC is 9e37%, and most cases of FVPTC are
diagnosed on FNAC as “suspicious for PTC,” “suspicious for
a follicular neoplasm,” or “atypia of unknown sig-
nificance.”2,11,12,15e19 Intraoperative FS analysis can
improve the diagnosis of FVPTC prior to thyroidectomy but
it is still limited, with one study reporting its sensitivity at
only 29%.15 The reasons for the low sensitivity of intra-
operative FS analysis are likely attributable to the loss of
nuclear and morphological features caused by freezing the
specimens, and the frequent appearance of encapsulated
tumors similar to that of follicular adenoma.15 Therefore,
owing to the low sensitivity of FS, many patients would
need to receive a second operation to complete total thy-
roidectomy if the primary tumor is >1 cm or if micro-
carcinoma with more than five foci is present, especially if
the size of the foci is 0.8e0.9 cm.20 Although completion of
thyroidectomy can be performed safely with low
morbidity,21 the second operation as a result of the low
sensitivity of intraoperative FS analysis may be more
problematic because of scarring, inflammation, bleeding in
the thyroid bed, and difficulty in identification of important
structures. A high degree of suspicion may increase the
accuracy of the diagnosis of FVPTC prior to or during sur-
gery. Nevertheless, similar to follicular carcinoma, FVPTC isal curves of patients with follicular variant of papillary thyroid
670 Y.-R. Li et al.often diagnosed only based on the final pathologically
permanent section.15
The results of this study revealed that the rate of distant
metastasis was higher than that of lymph node metastasis.
This result is similar to that of our previous study.22 A
prophylactic lymph node dissection was not performed in
our center without any evidence of lymph node involve-
ment except for T3 or T4 primary tumors. Therefore, it
could be the reason for low rate of lymph node metastasis.
Although FTC is known to metastasize via the hematoge-
nous spread, resulting in bone and lung metastases, such a
pattern is rare in C-PTC.23 FVPTC with higher rates of lung
and bone metastases compared with C-PTC has been re-
ported.24 In our study, the important findings were that
PTC-like nodules had significantly higher rates of both
lymph node metastasis and distant metastasis, that path-
ological angiolymphatic invasion was associated with the
higher rate of distant metastasis, and that almost an equal
ratio of pulmonary and bone metastases was observed.
These clinicopathological findings may suggest that FVPTC
has hybrid metastatic capacities with lymph node metas-
tasis via the lymphatic system similar to C-PTC, as well
distant metastasis via the bloodstream similar to FTC.
Reports in the literature have shown that encapsulated
FVPTC has a better prognosis than nonencapsulated
FVPTC.25,26 A previous clinicopathological study has shown
that the encapsulated or well-circumscribed form of
FVPTC very rarely metastasizes, whereas the infiltrative
form is associated with a significant risk of lymph node
metastasis.25 Nonencapsulation has been described as a
characteristic of the invasive form of FVPTC with a higher
rate of pulmonary metastasis than C-PTC.27 A limitation of
this study was that some of the specimens were difficult
to definitely classify into complete, partial, or infiltrative
forms by pathologists. Therefore, we classified specimens
into two main categories: encapsulation with thick fibrous
capsule (either partial or complete) and
nonencapsulation.
The rate of FVPTC with distant metastasis in this study
was obviously higher than that of a recent population-based
study, which reported a rate of 2%. However, the data in
this study are similar to those in our previous report.22
Tertiary referred center and pitfall in preoperative FNAC
of FVPTC are the main causes of the higher rate with
distant metastasis. Furthermore, although both race and
environment may contribute to the phenotype of the dis-
ease, more information is needed to confirm this.
According to the American Thyroid Association guide-
lines in 2009 for differentiated thyroid carcinoma, total or
near-total thyroidectomy is recommended if the primary
thyroid carcinoma is >1 cm. For 131I treatment of meta-
static disease, removal of all normal thyroid tissue is an
important intervention.28 Postoperative 131I ablation for all
patients with known distant metastases, gross extra-
thyroidal extension of the tumor regardless of tumor size,
primary tumor >4 cm, or primary tumor within 1e4 cm with
higher risk features is recommended in the revised guide-
lines published by the American Thyroid Association in
2009.29 As a result of this study, it was noted that FVPTC
patients with angiolymphatic invasion, extrathyroidal
extension, or nonencapsulation are at high risk of distant
metastasis. Therefore, in theory, patients with thesefeatures should receive 131I therapy and may benefit from a
larger first dose of 131I ablation postoperatively to destroy
suspecteddbut unprovendmetastatic disease promptly
and without delay. A further randomized controlled study is
necessary to confirm whether there is decreased morbidity
and mortality from a larger first dose of 131I ablation post-
operatively for FVPTC patients with the risk factors
mentioned in this study.
However, the major limitation of this study was the
small number of cases comprising the distant metastasis
group (n Z 32), and the 95% confidence interval was wide.
Although the result of our study showed these risk factors
to be statistically significant, they were still not so
conclusive. More cases gathered from multiple medical
centers in the future may provide more information to
confirm this result, because FVPTCs with distant metastasis
are rarely encountered in our clinical practice.
One-year overall survival was higher in FVPTC patients
with distant metastasis than in those without distant
metastasis (100% vs. 99.6%). The overall survival was
estimated by any cause of death, including trauma,
stroke, acute coronary syndrome, sepsis, and second ma-
lignancy, etc. A higher number of cases (n Z 314) was
found in the nondistant metastasis group than in the
distant metastasis group (n Z 32). One patient died of
nonthyroid carcinoma-associated disease; this was the
reason for the lower 1-year overall survival rate in the
nondistant metastasis group, however, it was not statis-
tically significant.
In summary, FVPTC has the hybrid clinical behavior
of C-PTC and FTC. The pathological findings of FVPTC
were associated with the clinical behavior in this study.
FVPTC patients with angiolymphatic invasion, extra-
thyroidal extension, or nonencapsulation had higher
rates of distant metastases, which resulted in poorer
prognosis. Patients with poorer prognosis should be
informed, and postoperative investigation for distant
metastasis may be warranted by the presence of these
two positive risk factors or the absence of one negative
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